All In MedTech

Device Trial Radar · NCT03084510

REPRISE China - Clinical Evaluation in China

REPRISE China: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Edge™ Valve System - Clinical Evaluation in China

Last checked: Nov 20, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Feb 28, 2020

Primary completion

Nov 30, 2020

Study completion Nov 30, 2020

Sponsor

Lead sponsor
Boston Scientific CorporationPublic (BSX)
Sponsor type
Industry
Collaborators
Quintiles, Inc.
First posted
Mar 21, 2017

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and effectiveness of the Lotus Edge™ Valve System for transcatheter aortic valve replacement (TAVR) in symptomatic Chinese patients with calcific, severe native aortic stenosis who are considered at high risk for surgical valve replacement.

Conditions

  • Stenoses, Aortic Valve

Interventions

  • Lotus Edge™ Valve SystemDevice

    • The Lotus Edge™ Valve System consisting of two main components: * a bioprosthetic bovine pericardial aortic valve, and * a delivery system Device sizes include 23 mm, 25 mm and 27 mm diameter.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortalityTime frame: Through 30 days post index procedure
  2. Mean aortic valve pressure gradientTime frame: At 30 days post index procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cardiovascular Institute and Fu Wai Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.